Core Viewpoint - MaxCyte, Inc. (MXCT) has received an upgrade to a Zacks Rank 1 (Strong Buy) due to an upward trend in earnings estimates, which is a significant factor influencing stock prices [1][3]. Earnings Estimates and Stock Performance - The Zacks rating system is based on changes in earnings estimates, which are closely correlated with near-term stock price movements [4][6]. - Rising earnings estimates for MaxCyte indicate an improvement in the company's underlying business, likely leading to increased stock prices [5][10]. Zacks Rank System - The Zacks Rank system classifies stocks into five groups based on earnings estimates, with Zacks Rank 1 stocks historically generating an average annual return of +25% since 1988 [7][9]. - Only the top 5% of Zacks-covered stocks receive a 'Strong Buy' rating, indicating superior earnings estimate revisions [9][10]. Recent Earnings Estimate Revisions - For the fiscal year ending December 2024, MaxCyte is expected to earn -$0.42 per share, reflecting a change of -13.5% from the previous year [8]. - Over the past three months, the Zacks Consensus Estimate for MaxCyte has increased by 0.8%, indicating positive sentiment among analysts [8].

Core Insights - MaxCyte, Inc. provided a preliminary update on its financial results for Q4 and the full year 2024, indicating a positive outlook for the cell therapy industry as it moves into 2025 [1][4]. Financial Performance - Total cash, cash equivalents, and investments as of December 31, 2024, are expected to be approximately $190 million, a decrease from $211 million on December 31, 2023, but higher than the updated guidance of $185 million [3]. - Core revenue for Q4 2024 is expected to be between $8.3 million and $8.5 million, compared to $7.2 million in Q4 2023 [6]. - Core revenue for the full year 2024 is expected to be between $32.2 million and $32.4 million, representing an 8 to 9% growth compared to $29.8 million for fiscal year 2023 [6]. Business Developments - The company increased the number of SPL customers by six in 2024 and supported the commercial launch of the first non-viral gene-edited cell therapy product approved by the FDA [4]. - MaxCyte's ExPERT™ platform is designed to support the expanding cell therapy market, facilitating the discovery, development, and commercialization of next-generation cell-based medicines [5].

Core Insights - MaxCyte, Inc. announced the retirement of Art Mandell from its Board of Directors effective December 31, 2024, after serving since 2006, contributing significantly to the company's growth and strategic direction [8][4][9] Company Overview - MaxCyte focuses on cell engineering, providing platform technologies to enhance the discovery, development, and commercialization of next-generation cell therapeutics [8] - The company has developed the ExPERT™ platform, which utilizes Flow Electroporation® technology, aimed at supporting the expanding cell therapy market [8][4] - The ExPERT family includes four instruments (ATx™, STx™, GTx™, VLx™), proprietary processing assemblies, and software protocols, backed by a strong intellectual property portfolio [8] Achievements - Under Mr. Mandell's leadership, MaxCyte achieved key milestones such as its initial public offering on the UK AIM exchange and US Nasdaq listing, the launch of the ExPERT™ platform, and signing 29 Strategic Platform Licenses with biotech companies [4][8] - The company also supported the first FDA-approved CRISPR edited non-viral cell therapy in the industry [4]

ROCKVILLE, Md., Nov. 13, 2024 (GLOBE NEWSWIRE) -- MaxCyte, Inc., (Nasdaq: MXCT; LSE: MXCT), a leading, cell-engineering focused company providing enabling platform technologies to advance the discovery, development and commercialization of next-generation cell therapeutics, marks the 25th anniversary of its founding this year. Over the past quarter-century, the company has remained steadfast in its mission to provide the life sciences community with the necessary technologies, as well as scientific, technic ...

MaxCyte, Inc. (MXCT) came out with a quarterly loss of $0.11 per share versus the Zacks Consensus Estimate of a loss of $0.13. This compares to loss of $0.11 per share a year ago. These figures are adjusted for non-recurring items.This quarterly report represents an earnings surprise of 15.38%. A quarter ago, it was expected that this company would post a loss of $0.14 per share when it actually produced a loss of $0.09, delivering a surprise of 35.71%.Over the last four quarters, the company has surpassed ...

Exhibit 99.1 MaxCyte Reports Third Quarter 2024 Financial Results and Updates Full Year 2024 Guidance ROCKVILLE, MD, November 6, 2024 — MaxCyte, Inc. (NASDAQ: MXCT; LSE: MXCT), a leading, cellengineering focused company providing enabling platform technologies to advance the discovery, development, and commercialization of next-generation cell therapeutics, today announced its financial results for the third quarter ended September 30, 2024, and updated its 2024 guidance. Third Quarter and Recent Highlights ...

ROCKVILLE, Md., Nov. 06, 2024 (GLOBE NEWSWIRE) -- MaxCyte, Inc. (NASDAQ: MXCT; LSE: MXCT), a leading, cell-engineering focused company providing enabling platform technologies to advance the discovery, development, and commercialization of next-generation cell therapeutics, today announced its financial results for the third quarter ended September 30, 2024, and updated its 2024 guidance. Third Quarter and Recent Highlights Total revenue of $8.2 million in the third quarter of 2024, an increase of 2% over t ...

ROCKVILLE, Md., Oct. 31, 2024 (GLOBE NEWSWIRE) -- MaxCyte, Inc., (Nasdaq: MXCT; LSE: MXCT), a leading, cell-engineering focused company providing enabling platform technologies to advance the discovery, development and commercialization of next-generation cell-based therapeutics, today announced Company management will participate at two upcoming investor conferences. Stifel 2024 Healthcare ConferenceFireside Chat on Monday, November 18th at 10:55 AM ET Stephens Annual Investment ConferenceFireside Chat on ...

MaxCyte, Inc. (MXCT) could be a solid choice for investors given its recent upgrade to a Zacks Rank #1 (Strong Buy). This upgrade primarily reflects an upward trend in earnings estimates, which is one of the most powerful forces impacting stock prices. The sole determinant of the Zacks rating is a company's changing earnings picture. The Zacks Consensus Estimate -- the consensus of EPS estimates from the sell-side analysts covering the stock -- for the current and following years is tracked by the system. I ...

ROCKVILLE, Md., Oct. 11, 2024 (GLOBE NEWSWIRE) -- MaxCyte, Inc., (NASDAQ: MXCT; LSE: MXCT), a leading, cell-engineering focused company providing enabling platform technologies to advance the discovery, development and commercialization of next-generation cell therapeutics and innovative bioprocessing applications, today announced that it will release financial results for the third quarter 2024 after the U.S. market close on Wednesday, November 6th, 2024. Company management will host a conference call to d ...